PD-1-cis IL-2R agonism yields better effectors from stem-like CD8

Antibodies, Blocking / immunology B7-H1 Antigen / antagonists & inhibitors CD8-Positive T-Lymphocytes / cytology Infections / drug therapy Interleukin-2 / immunology Interleukin-2 Receptor alpha Subunit / agonists Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Receptors, Interleukin-2 / agonists

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
10 2022

Historique:

received: 14 03 2021

accepted: 04 08 2022

pubmed: 29 9 2022

medline: 12 10 2022

entrez: 28 9 2022

Statut: ppublish

Résumé

Expansion and differentiation of antigen-experienced PD-1

Identifiants

DOI: 10.1038/s41586-022-05192-0 PMID: 36171284 PMC: PMC9534752

pubmed: 36171284

doi: 10.1038/s41586-022-05192-0

pii: 10.1038/s41586-022-05192-0

pmc: PMC9534752

doi:

Substances chimiques

Antibodies, Blocking 0

B7-H1 Antigen 0

Interleukin-2 0

Interleukin-2 Receptor alpha Subunit 0

Programmed Cell Death 1 Receptor 0

Receptors, Interleukin-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

161-172

Subventions

Organisme : NIH HHS

ID : P51 OD011132

Pays : United States

Organisme : NIH HHS

ID : S10 OD026799

Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Siddiqui, I. et al. Intratumoral Tcf1

pubmed: 30635237 doi: 10.1016/j.immuni.2018.12.021

Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465–470 (2019).

pubmed: 31827286 pmcid: 7108171 doi: 10.1038/s41586-019-1836-5

Miller, B. C. et al. Subsets of exhausted CD8

pubmed: 30778252 pmcid: 6673650 doi: 10.1038/s41590-019-0312-6

Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1

pubmed: 31810882 pmcid: 6920571 doi: 10.1016/j.immuni.2019.11.002

Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8

Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).

pubmed: 22343569 doi: 10.1038/nri3156

Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018).

pubmed: 30089912 doi: 10.1038/s41577-018-0046-y

Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306 (2017).

pubmed: 28405498 pmcid: 5384349 doi: 10.1080/2162402X.2016.1277306

Bentebibel, S. E. et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 9, 711–721 (2019).

pubmed: 30988166 doi: 10.1158/2159-8290.CD-18-1495

Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186–191 (2019).

pubmed: 30626941 pmcid: 6521699 doi: 10.1038/s41586-018-0830-7

West, E. E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604–2615 (2013).

pubmed: 23676462 pmcid: 3668811 doi: 10.1172/JCI67008

Mortara, L. et al. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front. Immunol. 9, 2905 (2018).

pubmed: 30619269 pmcid: 6305397 doi: 10.3389/fimmu.2018.02905

Waldhauer, I. et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 13, 1913791 (2021).

pubmed: 33974508 pmcid: 8115765 doi: 10.1080/19420862.2021.1913791

Inozume, T. et al. Selection of CD8

pubmed: 20948441 pmcid: 2980947 doi: 10.1097/CJI.0b013e3181fad2b0

Gros, A. et al. PD-1 identifies the patient-specific CD8

pubmed: 24667641 pmcid: 4001555 doi: 10.1172/JCI73639

Im, S. J. et al. Defining CD8

pubmed: 27501248 pmcid: 5297183 doi: 10.1038/nature19330

Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).

pubmed: 15322536 doi: 10.1038/nm1093

Facciabene, A., Motz, G. T. & Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162–2171 (2012).

pubmed: 22549946 pmcid: 3342842 doi: 10.1158/0008-5472.CAN-11-3687

Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3

pubmed: 15753206 pmcid: 2212841 doi: 10.1084/jem.20041982

Hirakawa, M. et al. Low-dose IL-2 selectively activates subsets of CD4

pubmed: 27812545 pmcid: 5085610 doi: 10.1172/jci.insight.89278

Yu, A., Olosz, F., Choi, C. Y. & Malek, T. R. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common γ-chain and a lymphoid cell environment. J. Immunol. 165, 2556–2562 (2000).

pubmed: 10946282 doi: 10.4049/jimmunol.165.5.2556

Hartmann, F. J. et al. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human T

pubmed: 25278028 doi: 10.1038/ncomms6056

Tamang, D. L. et al. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 36, 148–159 (2006).

pubmed: 17188506 pmcid: 1850105 doi: 10.1016/j.cyto.2006.11.008

Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484, 529–533 (2012).

pubmed: 22446627 pmcid: 3338870 doi: 10.1038/nature10975

Xu, Y. et al. An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity. Cancer Immunol. Res. 9, 1141–1157 (2021).

pubmed: 34376502 doi: 10.1158/2326-6066.CIR-21-0058

Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1

Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science 355, 1428–1433 (2017).

pubmed: 28280247 pmcid: 6286077 doi: 10.1126/science.aaf1292

Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science 355, 1423–1427 (2017).

pubmed: 28280249 pmcid: 5595217 doi: 10.1126/science.aaf0683

Schluns, K. S., Kieper, W. C., Jameson, S. C. & Lefrançois, L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat. Immunol. 1, 426–432 (2000).

pubmed: 11062503 doi: 10.1038/80868

Kaech, S. M. et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4, 1191–1198 (2003).

pubmed: 14625547 doi: 10.1038/ni1009

Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1

pubmed: 31810882 pmcid: 6920571 doi: 10.1016/j.immuni.2019.11.002

Zander, R. et al. CD4

pubmed: 31810883 pmcid: 6929322 doi: 10.1016/j.immuni.2019.10.009

Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498–1512 (2019).

pubmed: 31097342 pmcid: 6527362 doi: 10.1016/j.immuni.2019.04.010

Shulman, Z. et al. Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat. Immunol. 13, 67–76 (2011).

pubmed: 22138716 doi: 10.1038/ni.2173

Carlson, C. M. et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature 442, 299–302 (2006).

pubmed: 16855590 doi: 10.1038/nature04882

Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355–360 (2004).

pubmed: 14737169 doi: 10.1038/nature02284

Joshi, N. S. et al. Inflammation directs memory precursor and short-lived effector CD8

pubmed: 17723218 pmcid: 2034442 doi: 10.1016/j.immuni.2007.07.010

Sarkar, S. et al. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J. Exp. Med. 205, 625–640 (2008).

pubmed: 18316415 pmcid: 2275385 doi: 10.1084/jem.20071641

McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).

pubmed: 30676822 doi: 10.1146/annurev-immunol-041015-055318

Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301–318 (2018).

pubmed: 29414259 doi: 10.1146/annurev-med-012017-043208

Pereira, R. M., Hogan, P. G., Rao, A. & Martinez, G. J. Transcriptional and epigenetic regulation of T cell hyporesponsiveness. J. Leukoc. Biol. 102, 601–615 (2017).

pubmed: 28606939 pmcid: 5557644 doi: 10.1189/jlb.2RI0317-097R

Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8

pubmed: 27533016 doi: 10.1016/j.immuni.2016.07.021

He, R. et al. Follicular CXCR5-expressing CD8

pubmed: 27501245 doi: 10.1038/nature19317

Leong, Y. A. et al. CXCR5

pubmed: 27487330 doi: 10.1038/ni.3543

Wu, T. et al. The TCF1–Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).

pubmed: 28018990 pmcid: 5179228 doi: 10.1126/sciimmunol.aai8593

Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855 (2019).

pubmed: 31606264 pmcid: 6943829 doi: 10.1016/j.immuni.2019.09.013

Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733–14738 (2010).

pubmed: 20679213 pmcid: 2930455 doi: 10.1073/pnas.1009731107

Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).

pubmed: 31359002 pmcid: 6689255 doi: 10.1038/s41591-019-0522-3

Lucca, L. E. et al. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. J. Exp. Med. 218, e20200921 (2021).

pubmed: 33651881 pmcid: 7933991 doi: 10.1084/jem.20200921

Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8

pubmed: 34290406 pmcid: 9187974 doi: 10.1038/s41586-021-03704-y

Khushalani, N. I. et al. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: phase III PIVOT IO 001 study design. Future Oncol. 16, 2165–2175 (2020).

pubmed: 32723187 doi: 10.2217/fon-2020-0351

Onrust, S. V., Hartl, P. M., Rosen, S. D. & Hanahan, D. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97, 54–64 (1996).

pubmed: 8550850 pmcid: 507062 doi: 10.1172/JCI118406

Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003).

pubmed: 12663797 pmcid: 152117 doi: 10.1128/JVI.77.8.4911-4927.2003

Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).

pubmed: 29155950 doi: 10.1093/nar/gkx1098

Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357–360 (2015).

pubmed: 25751142 pmcid: 4655817 doi: 10.1038/nmeth.3317

Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

pubmed: 24227677 doi: 10.1093/bioinformatics/btt656

Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).

pubmed: 27207943 doi: 10.1093/bioinformatics/btw313

Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).

pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0

Madler, S. C. et al. Besca, a single-cell transcriptomics analysis toolkit to accelerate translational research. NAR Genom. Bioinform. 3, lqab102 (2021).

pubmed: 34761219 pmcid: 8573822 doi: 10.1093/nargab/lqab102

Sturm, G. et al. Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing data. Bioinformatics 36, 4817–4818 (2020).

pubmed: 32614448 pmcid: 7751015 doi: 10.1093/bioinformatics/btaa611